腹腔恶性肿瘤术后腹腔、淋巴、静脉联合化疗的临床研究及运用  

Abdominal cavity after abdominal cancer,lymph,intravenous chemotherapy for joint research and clinical use

作　　者：郝永钟 蒋壮志 殷容暖 解传仁 

机构地区：[1]广东省东莞市常平医院外二区普外科,510435

出　　处：《中国实用医药》2008年第22期47-48,共2页China Practical Medicine

基　　金：东莞市科技局医疗卫生类科研立项项目

摘　　要：目的研究腹腔胃肠道恶性肿瘤术后腹腔联合化疗较传统静脉全身化疗的优势。方法比较5年来腹腔恶性肿瘤根治术后腹腔联合化疗和静脉化疗的生存率复发率的差异。结果腹腔胃肠道恶性肿瘤术后腹腔联合化疗组患者1、2、3年生存率疗效明显高于静脉化疗组,复发率也具有显著性差异。结论胃肠道恶性肿瘤根治术后腹腔联合化疗优于静脉全身化疗。Objective To the advontage of research abdominal gastrointestinal cancer after abdominal chemotherapy than traditional intravenous chemotherapy. Methods Over the past five years compared abdominal gastrointestinal cancer after radical abdominal chemotherapy to intravenous chemotherapy and the survival rate of relapse rate differences. Results After abdominal gastrointestinal cancer in patients with abdominal chemotherapy group 1,2,3-year survival rate was significantly higher than the effect of intravenous chemotherapy, relapse rate also has significant differences. Conclusion The cure effect of gastrointestinal cancer after radi- cal abdominal chemotherapy is better than intravenous chemotherapy.

关 键 词：腹腔 恶性肿瘤 联合化疗 

分 类 号：R735[医药卫生—肿瘤] R730.56[医药卫生—临床医学]